A Study of Mirabegron (YM178) in Men With Lower Urinary Tract Symptoms (LUTS) and Bladder Outlet Obstruction (BOO)

• Status: Completed
• Trial end date: 2008-08-01
• Target enrollment: 0
• Participant gender: Male

Summary

This study examined the safety, tolerability, and efficacy of mirabegron (YM178) compared to placebo.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Astellas Pharma Inc
• Treatments: Mirabegron

Criteria

Inclusion Criteria:

• Men 45 years of age or older

• Documented bladder outlet obstruction

Exclusion Criteria:

• History of urinary retention

• Symptomatic and recurrent urinary tract infection (UTI)